A quiet revolution is underway in modern medicine: Drug development is aiming to move from managing disease to correcting it through RNA and gene-editing therapies. But delivering these treatments safely and precisely to the right cells remains a major hurdle—especially in hard-to-target organs like the brain and kidneys.